Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2624 · 1 trial · 1 indication
PANSS total score, sum of 30 item scores (each on a 0 to 7 scale), assesses positive and negative symptoms of psychopathology on a continuous scale from 0 (the best) to 210 (the worst). Day 28 value was calculated using last observation carried forward (LOCF). Change from baseline was calculated as Day 28 value minus baseline value.
| Arm | Type | Description |
|---|---|---|
| AZD2624 | EXPERIMENTAL | AZD2624 40 mg |
| Olanzapine | OTHER | Olanzapine 15 mg |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| Name | Type | Description |
|---|---|---|
| AZD2624 | DRUG | Oral Suspension |
| Olanzapine | DRUG | PO BID |
| Placebo | DRUG | - |
Inclusion Criteria: * Females of non-childbearing potential * Diagnosis of Schizophrenia Exclusion Criteria: * Clinically relevant disease and /or abnormalities. * Alcohol or substance abuse not in remission * Enrollment in another investigational study within 30 days
Top 15 of 16 competitors
AZD2624 was developed as an investigational treatment for schizophrenia. It is a small molecule therapy studied in adults with the condition. AstraZeneca PLC advanced it into Phase 2 clinical testing, and the program's single trial has been completed. It is not an approved medicine.
AZD2624 is made by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the drug's clinical development, including its Phase 2 study in schizophrenia. The compound is an AstraZeneca pipeline asset in the psychiatry therapeutic area.
AZD2624 reached Phase 2 development. Its one registered trial, a Phase 2A study in patients with schizophrenia, has been completed, and no trials are currently active. The drug remains investigational and has not been approved for any indication.
AZD2624 has been studied in one clinical trial, NCT00686998, titled Phase IIA Study in Patients With Schizophrenia. The trial was completed, enrolled 106 participants, and was randomized, double-blind, and placebo-controlled. It was conducted in the United States with participants aged 18 years and older.
AZD2624 is not an approved drug. It is an investigational small molecule that completed Phase 2 testing for schizophrenia, and its only registered trial is closed with no active studies. AstraZeneca has not brought it to market for any indication.